Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: BIOLOGICAL: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|DRUG: Placebo|DRUG: Aromatase inhibitor|DRUG: 5-Fluorouracil|DRUG: Carboplatin AUC|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Paclitaxel|DRUG: Trastuzumab
Sponsor: GlaxoSmithKline